List of investigational obsessive–compulsive disorder drugs
This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in September 2021. It is likely to become outdated with time.
Under development
[edit]Actively under development
[edit]- Immunoglobulin (immune globulin 10%, 10% high purity immunoglobulin, 10% IVIG, NewGam, Newnorm, Octagam 10%, Octagam, Panzyga) – immunoglobulin / immunostimulant [1][1]
- Troriluzole (BHV-4157, BHV-4157a, FC-4157; trigriluzole) – prodrug of riluzole / glutamate modulator [2][1]
Preclinical development
[edit]- Cannabis extracts (various) – cannabinoid receptor modulators [3]
No development reported
[edit]- 4'-Fluorocannabidiol (4'-F-CBD; fluorinated cannabidiol; HUF-101, HUF-102, HUF-103) – cannabinoid receptor modulator, other actions [4]
- AbbVie/Rugen research programme – unspecified mechanism of action [5]
- Agomelatine (Alodil, Melitor, Thymanax, Valdoxan, Vestin; AGO-178, AGO178C, S-20098, S-20098-F55) – serotonin 5-HT2C receptor antagonist and melatonin receptor agonist [6]
- CR-5542 – orexin receptor antagonist [7]
- Dual SSRIs and serotonin 5-HT1A receptor agonists (SSA-426, WAY-163426, WAY-211612, WAY-253752, WAY-426) [8]
- Risperidone (Risperdal, Risperdal Consta, Risperdal Depot; JNJ-410397-AAA, R-64766, R064766) – atypical antipsychotic / monoamine receptor modulator [9]
- Secretin (SecreFlo; INN-329, RG-1068) – hormone/diagnostic agent [10]
- Sosei Heptares research programme – various mechanisms of action [11]
Not under development
[edit]Development discontinued
[edit]- Bitopertin (R-1678, RG-6718, RG1678, RO-4917838) – glycine GlyT1 inhibitors / glycine reuptake inhibitor [12]
- Cycloserine (D-cycloserine; TIK-101) – glutamate NMDA receptor partial agonist [13]
- Elzasonan (CP-448187, CP-448187-01) – serotonin 5-HT1B and 5-HT1D receptor antagonist
- F-14258 – serotonin 5-HT1B and 5-HT1D receptor antagonist
- Fluoxetine/naltrexone (OREX-004) – selective serotonin reuptake inhibitor and opioid receptor antagonist [14]
- Mavoglurant (AFQ-056) – glutamate mGlu5 receptor antagonist [15]
- NPL-2003 – glutamate modulator [16]
- Ondansetron (Setrodon; TO-2061) – serotonin 5-HT3 receptor antagonist [17][1]
- RO-600175 – serotonin 5-HT2C receptor agonist [18]
- Roxindole (EMD-49980) – dopamine receptor agonist, serotonin receptor modulator, adrenergic receptor modulator, and serotonin reuptake inhibitor [19]
- SB-200646 (SB-200646A) – serotonin 5-HT2B and 5-HT2C receptor antagonist [20]
Formal development never or not yet started
[edit]- 5-HT6 receptor agonists (e.g., WAY-181187, WAY-208466)[2]
- Antiandrogens (e.g., flutamide, cyproterone acetate, triptorelin)[3]
- Cannabinoids (e.g., nabilone, tetrahydrocannabinol (THC)/cannabis) – cannabinoid receptor modulators[1]
- NMDA receptor modulators (e.g., ketamine, memantine, nitrous oxide, rapastinel)[1]
- Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., celecoxib, naproxen) – cyclooxygenase inhibitors[1]
- Rituximab (Rituxan) – monoclonal antibody against CD20[1]
- Serotonergic psychedelics (e.g., psilocybin/psilocybin mushrooms, lysergic acid diethylamide (LSD)) – serotonin receptor modulators[4][5][6][7][1]
- Tolcapone (Tasmar) – catechol-O-methyltransferase inhibitor[1]
Clinically used drugs
[edit]Approved drugs
[edit]- Clomipramine (Anafranil) – tricyclic antidepressant / monoamine reuptake inhibitor and receptor modulator [21]
- Escitalopram (S-citalopram; Cipralex, Entact, Lexapro, Seroplex, Sipralex, Sipralexa; LU-26054; MLD-55) – selective serotonin reuptake inhibitor [22]
- Fluoxetine (Prozac, Prozac Weekly, Reneuron, Sarafem; LY-110140) – selective serotonin reuptake inhibitor [23][24]
- Fluvoxamine (Depromel, Luvox, Luvox CR; SME-3110) – selective serotonin reuptake inhibitor and sigma-1 receptor agonist [25]
- Paroxetine (Aropax, Deroxat, Divarius, Dropax, Dropaxin, Frosinor, Motivan, Paxil, Paxil CR, Serestill, Seroxat, Tagonis; BRL-29060, BRL-29060A, FG-7051, NNC-207051, SI-211103) – selective serotonin reuptake inhibitor [26][27]
- Sertraline (Aremis, Besitran, Gladem, J Zoloft, Lustral, Serad, Serlain, Tatig, Zoloft; CP-51974, CP-51974-01) – selective serotonin reuptake inhibitor [28]
Off-label drugs
[edit]- Atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine, risperidone) – monoamine receptor modulators
See also
[edit]References
[edit]- ^ a b c d e f g h i Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". J Exp Pharmacol. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
- ^ Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson S, Beyer CE (May 2008). "Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466". Neuropsychopharmacology. 33 (6): 1323–35. doi:10.1038/sj.npp.1301503. PMID 17625499.
- ^ Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (2020). "Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review". Curr Med Chem. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.
- ^ Moreno FA, Wiegand CB, Taitano EK, Delgado PL (November 2006). "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder". J Clin Psychiatry. 67 (11): 1735–40. doi:10.4088/jcp.v67n1110. PMID 17196053.
- ^ Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (February 2021). "Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies". Acta Psychiatr Scand. 143 (2): 101–118. doi:10.1111/acps.13249. PMID 33125716. S2CID 226217912.
- ^ Odland AU, Kristensen JL, Andreasen JT (March 2021). "Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice". Behav Brain Res. 401: 113093. doi:10.1016/j.bbr.2020.113093. PMID 33359368. S2CID 229690041.
- ^ Castro Santos H, Gama Marques J (2021). "What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review". Porto Biomed J. 6 (1): e128. doi:10.1097/j.pbj.0000000000000128. PMC 8055489. PMID 33884324.
Further reading
[edit]- Berlin HA, Hamilton H, Hollander E (2008). "Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments". Mt Sinai J Med. 75 (3): 174–203. doi:10.1002/msj.20045. PMID 18704978.
- Marazziti D, Dell'Osso L (April 2015). "Why have early investigational therapies of obsessive-compulsive disorder failed to materialise?". Expert Opin Investig Drugs. 24 (4): 455–8. doi:10.1517/13543784.2015.1005735. PMID 25599971.
- Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". J Exp Pharmacol. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.